Greenphire, a provider of payment technologies for clinical trials, has entered a strategic partnership with Ernst & Young combining its eClinicalGPS technology with E&Y’s global intellectual property and advisory practice for clients in the pharmaceutical industries.
 
Greenphire’s clients will have access to E&Y’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance. Additionally, E&Y’s extensive research will be routed into a new Greenphire technology solution currently in development. The new web-based SaaS solution will manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all pharmaceutical operations.
 
Sam Whitaker, co-founder and chief executive officer of Greenphire, said, “We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”
 
Martin Holyoake, partner at Ernst & Young said, “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long-standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”